Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial
Table 2
Efficacy analysis.
Parameter
Median duration of treatment (weeks; range)
17 (6–116)
Cumulative dose of everolimus (mg; median, range)
1200 (440–8012)
Median duration of follow-up (weeks; range)
28 (17–147)
Best response by RECIST 1.0 (, %)
Complete response
0 (0)
Partial response
0 (0)
Stable disease
5 (71)
Progressive disease
2 (29)
Overall disease control
5 (71)
Median duration of SD (weeks; range)
24 (17–116)
Median PFS (weeks; 95% CI)
33 (8–56)
Median OS (weeks; 95% CI)
30 (15–45)
RECIST: Response Evaluation Criteria in Solid Tumors, SD: stable disease, PFS: progression-free survival, and OS: overall survival. 4 of 5 patients showed SD >24 weeks; at time of data analysis, 1 patient still had ongoing SD.
